Replies to post #242891 on Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

this of course is a complete joke. Is it meant that way? You cannot be serious. If it were easy to get money to pay the CRO it woulda been done a long time ago. Instead they are desperate for funds, totally desperate

[loanranger]

"there's a lot of PE capital out there looking for good risk/return."

There's little doubt about that. But as you said "Don't be misled by pumping".

A strategic clinical priority is not the same thing as a fait accomplis...it's just a fancy way of saying "here's what we'd like do".

“Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations—1) an oral pill for Kevetrin in Ovarian Cancer; 2) an oral pill for Brilacidin in IBD; and a topical application for Brilacidin in Atopic Dermatitis and Acne.”

The strategic clinical priority to analyze the Prurisol Phase 2b data in Psoriasis has been in place for many months and the recent 10-K said the following (I know it's boilerplate...but at this stage it is very real):
"The Company intends on financing its future development activities largely from a variety of sources, including the sale of equity securities and seeking relationships with partners to help fund future clinical trial costs. However, there is no assurance these plans will be realized and that any additional financing will be available to us on satisfactory terms and conditions, if at all."

So if as you say "there's a lot of PE capital out there looking for good risk/return" then someone needs to point them in this direction quickly. Your belief that the phrase "and, as additional funding becomes available" that appears in the statement that follows "to analyze the Prurisol Phase 2b data in Psoriasis" serves as some kind of evidence that funding already exists for that analysis seems pretty shaky to me given that there is no other evidence whatsoever to suggest it.

[scottsmith]

What kind of nonsense is this? Of course ipix is having major problems securing funding. How do I know? Because the prurisol data is still blinded.

[Amatuer17]

“They shouldn't be, there's a lot of PE capital out there looking for good risk/return.”

This is very true and it also highlights IPIX and Leo issue.

Look at Alzn acquisition of P1 product at $1.35 B valuation. It shows that if BP sees potential, they will enter into collaboration, BuyOut or fund trials.

Despite all the shouting by Leo on product potential, some good trial results - he is struggling to keep co running - not getting funds to even get results from CRO.

So it shows that no one believes the products or no one believes Leo in terms of what he is saying.
Either way we as SH are screwed

[djs7]

A comment (I believe) was made by the CEO about the blinded arms near the end of the Phase 2B ABSSSI trial and projection % chance of Brilacidin non-inferiority to Daptomycin.

Does anyone remember this...?

If so,
is IPIX allowed/not allowed to comment on blind data at end of Prurisol 2B trial based on this current CRO contract??

Is 57% Prurisol (2 arms) vs 43% placebo (1 arm) with only 300 mg Prurisol arm and placebo arm being equal in patient numbers not good enough to comment on blind data?

Believe Phase 2B ABSSSI was 3 out of 4 arms being Brilacidin with patient numbers in each of the 4 arms being about equal.